Search

Your search keyword '"Kadia, Tapan"' showing total 4,387 results
Start Over Author "Kadia, Tapan"
4,387 results on '"Kadia, Tapan"'

1. Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community

Author

Cuglievan, Branko, Kantarjian, Hagop, Rubnitz, Jeffrey E., Cooper, Todd M., Zwaan, C. Michel, Pollard, Jessica A., DiNardo, Courtney D., Kadia, Tapan M., Guest, Erin, Short, Nicholas J., McCall, David, Daver, Naval, Nunez, Cesar, Haddad, Fadi G., Garcia, Miriam, Bhalla, Kapil N., Maiti, Abhishek, Catueno, Samanta, Fiskus, Warren, Carter, Bing Z., Gibson, Amber, Roth, Michael, Khazal, Sajad, Tewari, Priti, Abbas, Hussein A., Bourgeois, Wallace, Andreeff, Michael, Shukla, Neerav N., Truong, Danh D., Connors, Jeremy, Ludwig, Joseph A., Stutterheim, Janine, Salzer, Elisabeth, Juul-Dam, Kristian L., Sasaki, Koji, Mahadeo, Kris M., Tasian, Sarah K., Borthakur, Gautam, Dickson, Samantha, Jain, Nitin, Jabbour, Elias, Meshinchi, Soheil, Garcia-Manero, Guillermo, Ravandi, Farhad, Stein, Eytan M., Kolb, E. Anders, and Issa, Ghayas C.

Published
2024
Full Text
View/download PDF

3. Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin

Author

Senapati, Jayastu, Jabbour, Elias, Short, Nicholas J., Jain, Nitin, Haddad, Fadi, Bathala, Tharakeswara, Kovalenko, Iuliia, Bidikian, Aram, Ravandi, Farhad, Khouri, Issa, Kadia, Tapan M., Garris, Rebecca, Montalban Bravo, Guillermo, Chien, Kelly, Shpall, Elizabeth, Kebriaei, Partow, and Kantarjian, Hagop M.

Published
2024
Full Text
View/download PDF

4. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia

Author

Montalban-Bravo, Guillermo, Rodriguez-Sevilla, Juan Jose, Swanson, David Michael, Kanagal-Shamanna, Rashmi, Hammond, Danielle, Chien, Kelly, Sasaki, Koji, Jabbour, Elias, DiNardo, Courtney, Takahashi, Koichi, Short, Nicholas, Issa, Ghayas C., Pemmaraju, Naveen, Kadia, Tapan, Ravandi, Farhad, Daver, Naval, Borthakur, Gautam, Loghavi, Sanam, Pierce, Sherry, Bueso-Ramos, Carlos, Kantarjian, Hagop, and Garcia-Manero, Guillermo

Published
2024
Full Text
View/download PDF

6. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia

Author

Kantarjian, Hagop, Haddad, Fadi G, Jain, Nitin, Sasaki, Koji, Short, Nicholas J, Loghavi, Sanam, Kanagal-Shamanna, Rashmi, Jorgensen, Jeffrey, Khouri, Issa, Kebriaei, Partow, Alvarado, Yesid, Kadia, Tapan, Paul, Shilpa, Garcia-Manero, Guillermo, Dabaja, Bouthaina, Yilmaz, Musa, Jacob, Jovitta, Garris, Rebecca, O’Brien, Susan, Ravandi, Farhad, and Jabbour, Elias

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Clinical Research, Rare Diseases, Stem Cell Research - Nonembryonic - Human, Pediatric Cancer, Stem Cell Research, Hematology, Childhood Leukemia, Cancer, Pediatric, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Adult, Humans, Antibodies, Bispecific, Cardiovascular Diseases, Inotuzumab Ozogamicin, Methotrexate, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Salvage Therapy, Blinatumomab, Chemo-immunotherapy, Inotuzumab, Outcome, Philadelphia-negative ALL, Salvage, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology, Oncology and carcinogenesis
Abstract

BackgroundHistorically, adults with relapsed-refractory acute lymphoblastic leukemia (ALL) experienced poor outcomes with intensive chemotherapy. This mature analysis explores the benefit of the addition of sequential blinatumomab to low-intensity mini-Hyper-CVD chemotherapy with inotuzumab ozogamicin in this setting.MethodsMini-Hyper-CVD (cyclophosphamide and dexamethasone at 50% dose reduction, no anthracycline, methotrexate at 75% dose reduction, cytarabine at 83% dose reduction) was combined with inotuzumab during the first 4 courses. From Patient #68 and onwards, inotuzumab was given in reduced and fractionated doses, and blinatumomab was added sequentially for 4 courses. Maintenance therapy with prednisone, vincristine, 6-mercaptopurine and methotrexate was given for 12 courses, and blinatumomab for 4 additional courses.ResultsAmong 110 patients (median age, 37 years) treated, 91 (83%) responded (complete response, 69 patients, 63%). Measurable residual disease negativity was documented in 75 patients (82% of responders). Fifty-three patients (48%) received allogeneic stem cell transplantation (SCT). Hepatic sinusoidal obstruction syndrome occurred in 9/67 patients (13%) on the original inotuzumab schedule and in 1/43 (2%) on the modified schedule. With a median follow-up of 48 months, the median overall survival (OS) was 17 months, and the 3 year OS was 40%. The 3 year OS was 34% with mini-Hyper-CVD plus inotuzumab and 52% with additional blinatumomab (P = 0.16). By landmark analysis at 4 months, the 3 year OS was 54%, similar between patients who did or did not receive allogeneic SCT.ConclusionLow-intensity mini-Hyper-CVD plus inotuzumab with or without blinatumomab showed efficacy in patients with relapsed-refractory ALL, with better survival after the addition of blinatumomab. Trial registration The trial was registered on clinicaltrials.gov with the identifier NCT01371630.

Published
2023

7. Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia

Author

Yeh, Jason, Pasvolsky, Oren, Saliba, Rima M., Figgins, Bradley, Wang, Christopher, Fang, Zhou, Ahmed, Sairah, Yilmaz, Musa, Daver, Naval, Ravandi, Farhad, DiNardo, Courtney, Short, Nicholas J., Kadia, Tapan, Al-Atrash, Gheath, Daher, May, Costa, David Marin, Popat, Uday, Champlin, Richard, Shpall, Elizabeth, and Oran, Betül

Published
2024
Full Text
View/download PDF

9. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm

Author

Bataller, Alex, Gener-Ricos, Georgina, Almanza-Huante, Emmanuel, Chien, Kelly S., Urrutia, Samuel, Bazinet, Alexandre, Rodriguez-Sevilla, Juan Jose, Hammond, Danielle, Sasaki, Koji, Takahashi, Koichi, DiNardo, Courtney D., Ravandi, Farhad, Borthakur, Gautam, Kadia, Tapan M., Kanagal-Shamanna, Rashmi, Kantarjian, Hagop M., Garcia-Manero, Guillermo, and Montalban-Bravo, Guillermo

Published
2024
Full Text
View/download PDF

12. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents

Author

Hammond, Danielle, Loghavi, Sanam, Wang, Sa A., Konopleva, Marina Y., Kadia, Tapan M., Daver, Naval G., Ohanian, Maro, Issa, Ghayas C., Alvarado, Yesid, Short, Nicholas J., Sasaki, Koji, Pemmaraju, Naveen, Montalban-Bravo, Guillermo, Lachowiez, Curtis A., Maiti, Abhishek, Garcia-Manero, Guillermo, Jabbour, Elias J., Borthakur, Gautam, Ravandi, Farhad, Takahashi, Koichi, Pierce, Sherry R., Kantarjian, Hagop M., and DiNardo, Courtney D.

Published
2023
Full Text
View/download PDF

14. T-prolymphocytic leukemia: TCL1 or MTCP1 rearrangement is not mandatory to establish diagnosis

Author

Fang, Hong, Beird, Hannah C., Wang, Sa A., Ibrahim, Andrew F., Tang, Zhenya, Tang, Guilin, You, M. James, Hu, Shimin, Xu, Jie, Li, Shaoying, Yin, C. Cameron, El Hussein, Siba, Le, Nhi, Futreal, P. Andrew, Bueso-Ramos, Carlos, Thakral, Beenu, Kadia, Tapan M., Thornton, Rebecca, Little, Latasha, Gumbs, Curtis, Song, Xingzhi, Medeiros, L. Jeffrey, and Wang, Wei

Published
2023
Full Text
View/download PDF

16. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

Author

Fiskus, Warren, Piel, Jessica, Collins, Mike, Hentemann, Murphy, Cuglievan, Branko, Mill, Christopher P., Birdwell, Christine E., Das, Kaberi, Davis, John A., Hou, Hanxi, Jain, Antrix, Malovannaya, Anna, Kadia, Tapan M., Daver, Naval, Sasaki, Koji, Takahashi, Koichi, Hammond, Danielle, Reville, Patrick K., Wang, Jian, Loghavi, Sanam, Sen, Rwik, Ruan, Xinjia, Su, Xiaoping, Flores, Lauren B., DiNardo, Courtney D., and Bhalla, Kapil N.

Published
2024
Full Text
View/download PDF

17. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study

Author

Bazinet, Alexandre, Garcia-Manero, Guillermo, Short, Nicholas, Alvarado, Yesid, Bataller, Alex, Abuasab, Tareq, Islam, Rabiul, Montalbano, Kathryn, Issa, Ghayas, Maiti, Abhishek, Yilmaz, Musa, Jain, Nitin, Masarova, Lucia, Kornblau, Steven, Jabbour, Elias, Montalban-Bravo, Guillermo, Rausch, Caitlin R, Pierce, Sherry, DiNardo, Courtney D, Kadia, Tapan, Daver, Naval, Konopleva, Marina, Huang, Xuelin, Kantarjian, Hagop, and Ravandi, Farhad

Published
2024
Full Text
View/download PDF

18. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study

Author

Bataller, Alex, Montalban-Bravo, Guillermo, Bazinet, Alexandre, Alvarado, Yesid, Chien, Kelly, Venugopal, Sangeetha, Ishizawa, Jo, Hammond, Danielle, Swaminathan, Mahesh, Sasaki, Koji, Issa, Ghayas C, Short, Nicholas J, Masarova, Lucia, Daver, Naval G, Kadia, Tapan M, Colla, Simona, Qiao, Wei, Huang, Xuelin, Kanagal-Shamanna, Rashmi, Hendrickson, Stephany, Ravandi, Farhad, Jabbour, Elias, Kantarjian, Hagop, and Garcia-Manero, Guillermo

Published
2024
Full Text
View/download PDF

19. Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)

Author

Kantarjian, Hagop M, Begna, Kebede H, Altman, Jessica K, Goldberg, Stuart L, Sekeres, Mikkael A, Strickland, Stephen A, Arellano, Martha L, Claxton, David F, Baer, Maria R, Gautier, Marc, Berman, Ellin, Seiter, Karen, Solomon, Scott R, Schiller, Gary J, Luger, Selina M, Butrym, Aleksandra, Gaidano, Gianluca, Thomas, Xavier G, Montesinos, Pau, Rizzieri, David A, Quick, Donald P, Venugopal, Parameswaran, Gaur, Rakesh, Maness, Lori J, Kadia, Tapan M, Ravandi, Farhad, Buyse, Marc E, and Chiao, Judy H

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Hematology, Clinical Trials and Supportive Activities, Clinical Research, Rare Diseases, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Aged, Arabinonucleosides, Azacitidine, Cytosine, Decitabine, Humans, Leukemia, Myeloid, Acute, Treatment Outcome, acute myeloid leukemia, decitabine, hypomethylation, sapacitabine, therapy, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Public health
Abstract

BackgroundAcute myeloid leukemia (AML) is fatal in elderly patients who are unfit for standard induction chemotherapy. The objective of this study was to evaluate the survival benefit of administering sapacitabine, an oral nucleoside analogue, in alternating cycles with decitabine, a low-intensity therapy, to elderly patients with newly diagnosed AML.MethodsThis randomized, open-label, phase 3 study (SEAMLESS) was conducted at 87 sites in 11 countries. Patients aged ≥70 years who were not candidates for or chose not to receive standard induction chemotherapy were randomized 1:1 to arm A (decitabine in alternating cycles with sapacitabine) received 1-hour intravenous infusions of decitabine 20 mg/m2 once daily for 5 consecutive days every 8 weeks (first cycle and subsequent odd cycles) and sapacitabine 300 mg twice daily on 3 consecutive days per week for 2 weeks every 8 weeks (second cycle and subsequent even cycles) or to control arm C who received 1-hour infusions of decitabine 20 mg/m2 once daily for 5 consecutive days every 4 weeks. Prior hypomethylating agent therapy for preexisting myelodysplastic syndromes or myeloproliferative neoplasms was an exclusion criterion. Randomization was stratified by antecedent myelodysplastic syndromes or myeloproliferative neoplasms, white blood cell count (

Published
2021

20. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax

Author

Bataller, Alex, Bazinet, Alexandre, DiNardo, Courtney D., Maiti, Abhishek, Borthakur, Gautam, Daver, Naval G., Short, Nicholas J., Jabbour, Elias J., Issa, Ghayas C., Pemmaraju, Naveen, Yilmaz, Musa, Montalban-Bravo, Guillermo, Takahashi, Koichi, Loghavi, Sanam, Garcia-Manero, Guillermo, Ravandi, Farhad, Kantarjian, Hagop M., and Kadia, Tapan M.

Published
2024
Full Text
View/download PDF

22. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia

Author

Senapati, Jayastu, Urrutia, Samuel, Loghavi, Sanam, Short, Nicholas J., Issa, Ghayas C., Maiti, Abhishek, Abbas, Hussein A., Daver, Naval G., Pemmaraju, Naveen, Pierce, Sherry, Chien, Kelly S., Sasaki, Koji, Kadia, Tapan M., Hammond, Danielle E., Borthakur, Gautam, Patel, Keyur, Ravandi, Farhad, Kantarjian, Hagop M., Garcia-Manero, Guillermo, and DiNardo, Courtney D.

Published
2023
Full Text
View/download PDF

23. Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation

Author

Short, Nicholas J., Ong, Faustine, Ravandi, Farhad, Nogueras-Gonzalez, Graciela, Kadia, Tapan M., Daver, Naval, DiNardo, Courtney D., Konopleva, Marina, Borthakur, Gautam, Oran, Betul, Al-Atrash, Gheath, Mehta, Rohtesh, Jabbour, Elias J., Yilmaz, Musa, Issa, Ghayas C, Maiti, Abhishek, Champlin, Richard E, Kantarjian, Hagop, Shpall, Elizabeth J, and Popat, Uday

Published
2023
Full Text
View/download PDF

24. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome

Author

DiNardo, Courtney D., Venugopal, Sangeetha, Lachowiez, Curtis, Takahashi, Koichi, Loghavi, Sanam, Montalban-Bravo, Guillermo, Wang, Xuemei, Carraway, Hetty, Sekeres, Mikkael, Sukkur, Ameenah, Hammond, Danielle, Chien, Kelly, Maiti, Abhishek, Masarova, Lucia, Sasaki, Koji, Alvarado, Yesid, Kadia, Tapan, Short, Nicholas J., Daver, Naval, Borthakur, Gautam, Ravandi, Farhad, Kantarjian, Hagop M., Patel, Bhumika, Dezern, Amy, Roboz, Gail, and Garcia-Manero, Guillermo

Published
2023
Full Text
View/download PDF

25. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial

Author

Jabbour, Elias, Short, Nicholas J, Senapati, Jayastu, Jain, Nitin, Huang, Xuelin, Daver, Naval, DiNardo, Courtney D, Pemmaraju, Naveen, Wierda, William, Garcia-Manero, Guillermo, Montalban Bravo, Guillermo, Sasaki, Koji, Kadia, Tapan M, Khoury, Joseph, Wang, Sa A, Haddad, Fadi G, Jacob, Jovitta, Garris, Rebecca, Ravandi, Farhad, and Kantarjian, Hagop M

Published
2023
Full Text
View/download PDF

26. Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia.

Author

Masarova, Lucia, Cortes, Jorge, Patel, Keyur, OBrien, Susan, Nogueras-Gonzalez, Graciela, Konopleva, Marina, Verstovsek, Srdan, Garcia-Manero, Guillermo, Ferrajoli, Alessandra, Kadia, Tapan, Ravandi-Kashani, Farhad, Borthakur, Gautam, DellaSala, Sara, Estrov, Zeev, Jabbour, Elias, and Kantarjian, Hagop

Subjects
chronic myeloid leukemia (CML), efficacy, frontline, nilotinib, safety, Adult, Antineoplastic Agents, Female, Humans, Leukemia, Myeloid, Chronic-Phase, Male, Middle Aged, Protein Kinase Inhibitors, Pyrimidines, Time, Treatment Outcome
Abstract

BACKGROUND: Nilotinib is a potent, second-generation inhibitor of BCR-ABL1 tyrosine kinase and has been approved as frontline and salvage therapy for patients with chronic-phase chronic myeloid leukemia (CP-CML). METHODS: In this single-institution, phase 2 study, 122 patients with newly diagnosed CP-CML received nilotinib 400 mg twice daily. The median follow-up on study was 78.3 months (interquartile range, 58.4-96.5 months). RESULTS: Fifty-six percent of patients remained on therapy at the last follow-up. Both the complete cytogenetic response rate and the major molecular response (MR) rate were 91%. Seventy-five percent and 59% of patients achieved a ≥4.5-log reduction in BCR-ABL1 transcripts (MR4.5) and a sustained MR4.5 beyond 2 years, respectively. The estimated event-free survival and overall survival rates at 5 years were 89% and 93%, respectively, and the corresponding rates at 10 years were 85% and 88%, respectively. Treatment discontinuation due to toxicity occurred in 19% of patients, mostly because of cardiovascular events (10%) and biochemical abnormalities (6%). The top 3 nonhematologic toxicities were rash (55%), elevated bilirubin (57%), and elevated aminotransferases (48%). Hematologic toxicity was transient and mild. Ischemic cardiovascular adverse events occurred in 8% of patients. Four patients (3%) progressed to accelerated or blast phase while on therapy, and 7 patients (6%) died on study. CONCLUSIONS: The current data confirm the long-term efficacy of nilotinib 400 mg twice daily in patients with CP-CML. A majority of patients can achieve sustained MR4.5.

Published
2020

27. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL

Author

Jain, Nitin, Senapati, Jayastu, Thakral, Beenu, Ferrajoli, Alessandra, Thompson, Philip, Burger, Jan, Basu, Sreyashi, Kadia, Tapan, Daver, Naval, Borthakur, Gautam, Konopleva, Marina, Pemmaraju, Naveen, Parry, Erin, Wu, Catherine J., Khoury, Joseph, Bueso-Ramos, Carlos, Garg, Naveen, Wang, Xuemei, Lopez, Wanda, Ayala, Ana, O’Brien, Susan, Kantarjian, Hagop, Keating, Michael, Allison, James, Sharma, Padmanee, and Wierda, William

Published
2023
Full Text
View/download PDF

28. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Author

Issa, Ghayas C., Bidikian, Aram, Venugopal, Sangeetha, Konopleva, Marina, DiNardo, Courtney D., Kadia, Tapan M., Borthakur, Gautam, Jabbour, Elias, Pemmaraju, Naveen, Yilmaz, Musa, Short, Nicholas J., Maiti, Abhishek, Sasaki, Koji, Masarova, Lucia, Pierce, Sherry, Takahashi, Koichi, Tang, Guilin, Loghavi, Sanam, Patel, Keyur, Andreeff, Michael, Bhalla, Kapil, Garcia-Manero, Guillermo, Ravandi, Farhad, Kantarjian, Hagop, and Daver, Naval

Published
2023
Full Text
View/download PDF

30. High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance

Author

Yang, Hui, Garcia-Manero, Guillermo, Sasaki, Koji, Montalban-Bravo, Guillermo, Tang, Zhenya, Wei, Yue, Kadia, Tapan, Chien, Kelly, Rush, Diana, Nguyen, Ha, Kalia, Awdesh, Nimmakayalu, Manjunath, Bueso-Ramos, Carlos, Kantarjian, Hagop, Medeiros, L. Jeffrey, Luthra, Rajyalakshmi, and Kanagal-Shamanna, Rashmi

Published
2022
Full Text
View/download PDF

31. Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity

Author

Bazinet, Alexandre, Kadia, Tapan, Short, Nicholas J., Borthakur, Gautam, Wang, Sa A., Wang, Wei, Loghavi, Sanam, Jorgensen, Jeffrey, Patel, Keyur, DiNardo, Courtney, Daver, Naval, Alvarado, Yesid, Haddad, Fadi G., Pierce, Sherry, Gonzalez, Graciela Nogueras, Maiti, Abhishek, Sasaki, Koji, Yilmaz, Musa, Thompson, Philip, Wierda, William, Garcia-Manero, Guillermo, Andreeff, Michael, Jabbour, Elias, Konopleva, Marina, Huang, Xuelin, Kantarjian, Hagop, and Ravandi, Farhad

Published
2023
Full Text
View/download PDF

32. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial

Author

Jabbour, Elias, Short, Nicholas J, Jain, Nitin, Huang, Xuelin, Montalban-Bravo, Guillermo, Banerjee, Pinaki, Rezvani, Katayoun, Jiang, Xianli, Kim, Kun Hee, Kanagal-Shamanna, Rashmi, Khoury, Joseph D, Patel, Keyur, Kadia, Tapan M, Daver, Naval, Chien, Kelly, Alvarado, Yesid, Garcia-Manero, Guillermo, Issa, Ghayas C, Haddad, Fadi G, Kwari, Monica, Thankachan, Jennifer, Delumpa, Ricardo, Macaron, Walid, Garris, Rebecca, Konopleva, Marina, Ravandi, Farhad, and Kantarjian, Hagop

Published
2023
Full Text
View/download PDF

33. TP53 Y220C mutations in patients with myeloid malignancies

Author

Gener-Ricos, Georgina, primary, Bewersdorf, Jan P., additional, Loghavi, Sanam, additional, Bataller, Alex, additional, Goldberg, Aaron D., additional, Famulare, Christopher, additional, Takahashi, Koichi, additional, Issa, Ghayas C., additional, Borthakur, Gautam, additional, Kadia, Tapan M., additional, Short, Nicholas J., additional, Senapati, Jayastu, additional, Carter, Bing Z., additional, Patel, Keyur P., additional, Kantarjian, Hagop, additional, Andreeff, Michael, additional, Stein, Eytan M., additional, and DiNardo, Courtney D., additional

Published
2024
Full Text
View/download PDF

34. Detection of PNH clones can aid in the distinction of aplastic anemia vs inherited BM failure syndromes: a single center experience and review of the literature.

Author

Nasnas, Patrice, primary, Ling, Jianhua, additional, Gerstein, Yoheved, additional, Wang, Sa A., additional, Loghavi, Sanam, additional, Hammond, Danielle, additional, Montalban-Bravo, Guillermo, additional, Senapati, Jayastu, additional, Pemmaraju, Naveen, additional, Corredor, Jessie, additional, Pierce, Sherry, additional, Roth, Michael, additional, Ravandi, Farhad, additional, Cuglievan, Branko, additional, Kadia, Tapan, additional, and DiNardo, Courtney D, additional

Published
2024
Full Text
View/download PDF

35. Mutation patterns and prognostic implications in acute myeloid leukemia with chromosomal 7 deletions.

Author

Kugler, Eitan, primary, Dasdemir, Enes, additional, Wang, Bofei, additional, Bataller, Alex, additional, Dinardo, Courtney Denton, additional, Daver, Naval Guastad, additional, Yilmaz, Musa, additional, Short, Nicholas James, additional, Kadia, Tapan M., additional, Sasaki, Koji, additional, Bazinet, Alexandre, additional, Pierce, Sherry, additional, Reville, Patrick Kevin, additional, Ravandi-Kashani, Farhad, additional, and Abbas, Hussein, additional

Published
2024
Full Text
View/download PDF

36. FLAG-IDA + venetoclax in newly diagnosed (ND) or relapsed/refractory (RR) AML.

Author

Jen, Wei Ying, primary, Takahashi, Koichi, additional, Loghavi, Sanam, additional, Kadia, Tapan M., additional, Daver, Naval Guastad, additional, Xiao, Lianchun, additional, Short, Nicholas James, additional, Borthakur, Gautam, additional, Issa, Ghayas C., additional, Pemmaraju, Naveen, additional, Reville, Patrick Kevin, additional, Bravo, Guillermo Montalban, additional, Yilmaz, Musa, additional, Garcia-Manero, Guillermo, additional, Ravandi-Kashani, Farhad, additional, Konopleva, Marina, additional, Mullin, Jillian K, additional, Pierce, Sherry, additional, Kantarjian, Hagop M., additional, and Dinardo, Courtney Denton, additional

Published
2024
Full Text
View/download PDF

37. Outcomes of patients with bone marrow fibrosis in de novo and secondary acute myeloid leukemia.

Author

Urrutia, Samuel, primary, Kantarjian, Hagop M., additional, Ravandi-Kashani, Farhad, additional, Jabbour, Elias, additional, Kanagal-Shamanna, Rashmi, additional, Loghavi, Sanam, additional, Patel, Keyur P., additional, Montalban-Bravo, Guillermo, additional, Short, Nicholas James, additional, Daver, Naval Guastad, additional, Borthakur, Gautam, additional, Dinardo, Courtney Denton, additional, Kadia, Tapan M., additional, Masarova, Lucia, additional, Bose, Prithviraj, additional, Pemmaraju, Naveen, additional, Garcia-Manero, Guillermo, additional, and Sasaki, Koji, additional

Published
2024
Full Text
View/download PDF

38. A retrospective comparison of abbreviated course “7+7” vs standard hypomethylating agent plus venetoclax doublets in older/unfit patients with newly diagnosed acute myeloid leukemia.

Author

Bazinet, Alexandre, primary, Dinardo, Courtney Denton, additional, Arani, Naszrin, additional, Bataller, Alex, additional, Rausch, Caitlin R, additional, Maiti, Abhishek, additional, Swaminathan, Mahesh, additional, Daver, Naval Guastad, additional, Kadia, Tapan M., additional, Ravandi-Kashani, Farhad, additional, Kantarjian, Hagop M., additional, Chraibi, Samy, additional, Decroocq, Justine, additional, Pascal, Laurent, additional, Lebon, Delphine, additional, Bonnet, Sarah, additional, Gauthier, Nicolas, additional, Pages, Arnaud, additional, De Botton, Stéphane, additional, and Willekens, Christophe, additional

Published
2024
Full Text
View/download PDF

39. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial

Author

Jabbour, Elias, Short, Nicholas J, Jain, Nitin, Thompson, Philip A, Kadia, Tapan M, Ferrajoli, Alessandra, Huang, Xuelin, Yilmaz, Musa, Alvarado, Yesid, Patel, Keyur P, Garcia-Manero, Guillermo, Macaron, Walid, Garris, Rebecca, Konopleva, Marina, Ravandi, Farhad, and Kantarjian, Hagop

Published
2022
Full Text
View/download PDF

40. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.

Author

Jabbour, Elias, Sasaki, Koji, Ravandi, Farhad, Short, Nicholas, Garcia-Manero, Guillermo, Daver, Naval, Kadia, Tapan, Konopleva, Marina, Jain, Nitin, Cortes, Jorge, Issa, Ghayas, Jacob, Jovitta, Kwari, Monica, Thompson, Philip, Garris, Rebecca, Pemmaraju, Naveen, Yilmaz, Musa, Kantarjian, Hagop, and OBrien, Susan

Subjects
blinatumomab, inotuzumab, mini-hyperfractionated cyclophosphamide, vincristine, and dexamethasone (mini-HCVD), older acute lymphoblastic leukemia (ALL), outcome, Aged, Aged, 80 and over, Antibodies, Bispecific, Antineoplastic Agents, Immunological, Female, Humans, Inotuzumab Ozogamicin, Male, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Propensity Score, Survival Rate
Abstract

BACKGROUND: The outcome of older patients with newly diagnosed, Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) is poor. The combination of targeted therapy with low-intensity chemotherapy is safe and effective. The objective of the current analysis was to compare the outcome of patients who received a combination of inotuzumab ozogamicin plus low-intensity chemotherapy (mini-hyperfractionated cyclophosphamide, vincristine, and dexamethasone [mini-HCVD]) with or without blinatumomab versus the outcome of those who received the standard, intensive, hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (HCVAD) regimen. METHODS: The authors analyzed 135 older patients with newly diagnosed, Ph-negative ALL who were treated prospectively with standard HCVAD (n = 77) or with the combination of inotuzumab ozogamicin plus mini-HCVD with or without blinatumomab (n = 58). A propensity score analysis was conducted using 1:1 matching using the nearest neighbor matching method. RESULTS: Propensity score matching identified 38 patients in each cohort. The antibody plus low-intensity chemotherapy combination induced higher response rates (98% vs 88%), with lower rates of early death (0% vs 8%) and lower rates of death in complete remission (5% vs 17%). With propensity score matching, the 3-year event-free survival rates for patients who received HCVAD and those who received the combination of inotuzumab ozogamicin plus mini-HCVD with or without blinatumomab were 34% and 64%, respectively (P = .003), and the 3-year overall survival rates were 34% and 63%, respectively (P = .004). By multivariate analysis, age (P = .019; hazard ratio, 1.045) and the combination of inotuzumab plus mini-HCVD with or without blinatumomab (P = .020; hazard ratio, 0.550) were identified as independent prognostic factors for survival. CONCLUSIONS: The combination of inotuzumab ozogamicin plus mini-HCVD with or without blinatumomab is safe and effective in older patients with newly diagnosed, Ph-negative ALL and confers a better outcome compared with standard HCVAD chemotherapy.

Published
2019

41. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Author

Jain, Preetesh, Kantarjian, Hagop, Boddu, Prajwal C, Nogueras-González, Graciela M, Verstovsek, Srdan, Garcia-Manero, Guillermo, Borthakur, Gautam, Sasaki, Koji, Kadia, Tapan M, Sam, Princy, Ahaneku, Hycienth, O'Brien, Susan, Estrov, Zeev, Ravandi, Farhad, Jabbour, Elias, and Cortes, Jorge E

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Cardiovascular, Hematology, Rare Diseases, Adult, Antineoplastic Agents, Cardiovascular Diseases, Dasatinib, Female, Humans, Imatinib Mesylate, Imidazoles, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Male, Middle Aged, Protein Kinase Inhibitors, Pyridazines, Pyrimidines, Thrombosis, Treatment Outcome, Cardiovascular medicine and haematology
Abstract

Cardiovascular or arteriothrombotic adverse events (CV- or AT-AEs) are reported in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). The incidence and characteristics across different TKI have not been systematically analyzed. We analyzed 531 patients treated with frontline TKIs in different prospective trials: imatinib 400 mg (n = 71) and 800 mg (n = 203), nilotinib (n = 108), dasatinib (n = 106), and ponatinib (n = 43). Characteristics and incidence of new-onset CV-AEs and AT-AEs were analyzed. Poisson regression models assessed factors associated with AE incidence. Median follow-up was 94 months (range, 2-195). Overall, 237 patients (45%) developed CV-AEs and 46 (9%) developed AT-AEs. Hypertension was the most common AE seen in 175 patients (33%; grade 3/4 in 17%). CV-AE and AT-AE incidence ratios (IRs) with 95% confidence intervals (CIs) were 8.6 (7.6-9.8) and 1.7 (1.2-2.2) per 100 person-years. Among the TKIs, ponatinib showed the highest IR (95% CI) for CV-AEs and AT-AEs at 40.7 (27.9-59.4) and 9.0 (4.1-20.1). In multivariate analysis, ponatinib therapy was associated with increased incidence rate ratio (IRR) for CV-AEs (4.62; 95% CI, 2.7-7.7; P < .0001) and AT-AEs (6.38; 95% CI, 1.8-21.8; P < .0001) compared with imatinib 400. In summary, there is an increased risk of CV-AEs (except hypertension) and AT-AEs in CML patients treated with newer TKIs, particularly with ponatinib. Patients on TKIs must be informed and closely monitored for vascular AEs. These studies were registered at www.clinicaltrials.gov as #NCT00048672, #NCT00038649, #NCT00050531, #NCT00254423, #NCT00129740, and #NCT01570868.

Published
2019

42. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms

Author

Sperling, Adam S., Guerra, Veronica A., Kennedy, James A., Yan, Yuanqing, Hsu, Joanne I., Wang, Feng, Nguyen, Andrew T., Miller, Peter G., McConkey, Marie E., Quevedo Barrios, Vanessa A., Furudate, Ken, Zhang, Linda, Kanagal-Shamanna, Rashmi, Zhang, Jianhua, Little, Latasha, Gumbs, Curtis, Daver, Naval, DiNardo, Courtney D., Kadia, Tapan, Ravandi, Farhad, Kantarjian, Hagop, Garcia-Manero, Guillermo, Futreal, P. Andrew, Ebert, Benjamin L., and Takahashi, Koichi

Published
2022
Full Text
View/download PDF

43. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 study

Author

Bazinet, Alexandre, Darbaniyan, Faezeh, Jabbour, Elias, Montalban-Bravo, Guillermo, Ohanian, Maro, Chien, Kelly, Kadia, Tapan, Takahashi, Koichi, Masarova, Lucia, Short, Nicholas, Alvarado, Yesid, Yilmaz, Musa, Ravandi, Farhad, Andreeff, Michael, Kanagal-Shamanna, Rashmi, Ganan-Gomez, Irene, Colla, Simona, Qiao, Wei, Huang, Xuelin, McCue, Deborah, Mirabella, Bailey, Kantarjian, Hagop, and Garcia-Manero, Guillermo

Published
2022
Full Text
View/download PDF

44. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

Author

Short, Nicholas J., Kantarjian, Hagop, Ravandi, Farhad, Konopleva, Marina, Jain, Nitin, Kanagal-Shamanna, Rashmi, Patel, Keyur P., Macaron, Walid, Kadia, Tapan M., Wang, Sa, Jorgensen, Jeffrey L., Khoury, Joseph D., Yilmaz, Musa, Kebriaei, Partow, Takahashi, Koichi, Garcia-Manero, Guillermo, Daver, Naval, Post, Sean M., Huang, Xuelin, Kornblau, Steven M., Pelletier, Sara, Flores, Wilmer, Matthews, Jairo, Garris, Rebecca, and Jabbour, Elias

Published
2022
Full Text
View/download PDF

48. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure

Author

Short, Nicholas J., Venugopal, Sangeetha, Qiao, Wei, Kadia, Tapan M., Ravandi, Farhad, Macaron, Walid, Dinardo, Courtney D., Daver, Naval, Konopleva, Marina, Borthakur, Gautam, Shpall, Elizabeth J., Popat, Uday, Champlin, Richard E., Mehta, Rohtesh, Al-Atrash, Gheath, Oran, Betul, Jabbour, Elias, Garcia-Manero, Guillermo, Issa, Ghayas C., Montalban-Bravo, Guillermo, Yilmaz, Musa, Maiti, Abhishek, and Kantarjian, Hagop

Published
2022
Full Text
View/download PDF

50. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study

Author

Lachowiez, Curtis A, Reville, Patrick K, Kantarjian, Hagop, Jabbour, Elias, Borthakur, Gautam, Daver, Naval, Loghavi, Sanam, Furudate, Ken, Xiao, Lianchun, Pierce, Sherry, Short, Nicholas J, Maiti, Abhishek, Yilmaz, Musa, Sasaki, Koji, Takahashi, Koichi, Konopleva, Marina, Pemmaraju, Naveen, Popat, Uday, Shpall, Elizabeth, Garcia-Manero, Guillermo, Ravandi, Farhad, DiNardo, Courtney D, and Kadia, Tapan M

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results